BIT Share Price

Open 0.03 Change Price %
High 0.03 1 Day 0.00 0.00
Low 0.03 1 Week 0.00 0.00
Close 0.03 1 Month 0.01 50.00
Volume 1767502 1 Year -0.01 -25.00
52 Week High 0.05
52 Week Low 0.02
BIT Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.03
Support 1 0.03
Support 2 0.03
ASX Australia Most Active Stocks
COE 0.30 3.45%
COE 0.30 3.45%
GPP 0.02 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
XST 0.02 100.00%
XST 0.02 100.00%
ATP 0.03 50.00%
ATP 0.03 50.00%
PMQ 0.03 50.00%
RMI 0.03 50.00%
RMI 0.03 50.00%
BNV 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
GDY 0.01 -50.00%
More..

Biotron Ltd (ASX: BIT)

BIT Technical Analysis 2
As on 1st Nov 2017 BIT Share Price closed @ 0.03 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.03 & Strong Buy for SHORT-TERM with Stoploss of 0.02 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIT Target for November
1st Target up-side 0.04
2nd Target up-side 0.05
3rd Target up-side 0.06
1st Target down-side 0.02
2nd Target down-side 0.01
3rd Target down-side N/A
BIT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotron.com.au
BIT Address
BIT
56 Delhi Road
Suite 19
North Ryde, NSW 2113
Australia
Phone: 61 2 9805 0488
Fax: 61 2 9805 0688
BIT Latest News
Interactive Technical Analysis Chart Biotron Ltd ( BIT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotron Ltd
BIT Business Profile
Biotron Limited develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1 in Australia. Its lead drug includes the BIT225, a viroporin inhibitor, which is in Phase 2 clinical trials used for the treatment of HCV and HIV infections. The company also has a portfolio of clinical and preclinical antiviral programs developing drugs targeting HCV, HIV, Dengue virus, and Influenza virus. Biotron Limited is based in North Ryde, Australia.